Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SWTX Stock Forecast 2026-2027
$46.99
Current Price
$3.54B
Market Cap
Buy 0
Hold 6
Sell 0
Wall St Analyst Ratings
Distance to SWTX Price Targets
+0.0%
To High Target of $47.00
+0.0%
To Median Target of $47.00
+0.0%
To Low Target of $47.00
SWTX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+35.7%
1 Year Change
0.0%
Year-to-Date Change
-24.2%
From 52W High of $62.00
+66.6%
From 52W Low of $28.21
📊 TOP ANALYST CALLS
Did SWTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if SpringWorks is one of their latest high-conviction picks.
Latest SWTX Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, SWTX has a neutral consensus with a median price target of $47.00 (ranging from $47.00 to $47.00). The overall analyst rating is N/A (N/A/10). Currently trading at $46.99, the median forecast implies a 0.0% upside. This outlook is supported by 0 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Michael Schmidt at Guggenheim, projecting a 0.0% upside. Conversely, the most conservative target is provided by Michael Schmidt at Guggenheim, suggesting a 0.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SWTX Analyst Ratings
0
Buy
6
Hold
0
Sell
SWTX Price Target Range
Low
$47.00
Average
$47.00
High
$47.00
Current: $46.99
Latest SWTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SWTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 12, 2025 | Guggenheim | Michael Schmidt | Neutral | Reiterates | $47.00 |
| Apr 30, 2025 | HC Wainwright & Co. | Robert Burns | Neutral | Downgrade | $47.00 |
| Apr 29, 2025 | Guggenheim | Michael Schmidt | Neutral | Downgrade | $47.00 |
| Apr 29, 2025 | TD Cowen | Yaron Werber | Hold | Downgrade | $47.00 |
| Apr 28, 2025 | Barclays | Peter Lawson | Equal-Weight | Downgrade | $47.00 |
| Feb 24, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Feb 12, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Feb 12, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $77.00 |
| Feb 12, 2025 | Evercore ISI Group | Cory Kasimov | Outperform | Maintains | $65.00 |
| Jan 8, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $78.00 |
| Nov 20, 2024 | Evercore ISI Group | Cory Kasimov | Outperform | Initiates | $60.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $74.00 |
| Sep 4, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $68.00 |
| Aug 28, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $76.00 |
| Jun 4, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| May 31, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| May 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $74.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $74.00 |
| Mar 6, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $75.00 |
SpringWorks Therapeutics Inc. (SWTX) Competitors
The following stocks are similar to SpringWorks based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SpringWorks Therapeutics Inc. (SWTX) Financial Data
Valuation Metrics
Market Cap
$3.54B
Enterprise Value
$3.26B
P/E Ratio
N/A
PEG Ratio
-22.0x
Price/Sales
16.1x
Growth & Margins
Revenue Growth (YoY)
+133.7%
Gross Margin
+92.8%
Operating Margin
-164.1%
Net Margin
-115.6%
EPS Growth
+133.7%
Financial Health
Cash/Price Ratio
+8.1%
Current Ratio
4.3x
Debt/Equity
1.8x
ROE
-51.6%
ROA
-28.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
SpringWorks Therapeutics Inc. (SWTX) Business Model
About SpringWorks Therapeutics Inc.
What They Do
Develops innovative medicines for rare diseases.
Business Model
SpringWorks Therapeutics generates revenue by developing and commercializing therapies for rare diseases, focusing on unmet medical needs. The company leverages partnerships and collaborations to enhance its research capabilities and expand its therapeutic pipeline, aiming to bring effective treatments to market efficiently.
Additional Information
The company's emphasis on genomic-driven oncology and rare genetic diseases positions it strategically within the biopharmaceutical industry, where there is a significant demand for novel solutions. SpringWorks plays a crucial role in enhancing patient outcomes through its commitment to translating scientific discoveries into viable treatments.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
368
CEO
Mr. Saqib Islam J.D.
Country
United States
IPO Year
2019
Website
www.springworkstx.comSpringWorks Therapeutics Inc. (SWTX) Latest News & Analysis
Latest News
Quick Summary
Long-term OGSIVEO treatment for up to 4 years showed tumor size reductions, increased response rates, improved symptoms in desmoid tumors, and a consistent safety profile.
Why It Matters
Positive clinical results for OGSIVEO may boost investor confidence in the company's future revenue potential and stock value, indicating strong demand for effective cancer treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors
5 months ago
Quick Summary
OGSIVEO has received EU marketing authorization, making it the first and only therapy approved for treating desmoid tumors.
Why It Matters
OGSIVEO's EU marketing authorization for desmoid tumors opens a unique market opportunity, potentially boosting revenue and market share for the company involved, attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
EZMEKLY has received EU marketing authorization as the first therapy approved for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder.
Why It Matters
EZMEKLY's EU approval for NF1-PN positions it uniquely in the market, potentially driving significant revenue growth and enhancing the company's valuation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Merck KGaA has completed the acquisition of SpringWorks Therapeutics for $3.4 billion, following the necessary regulatory approvals and closing conditions.
Why It Matters
Merck KGaA's $3.4 billion acquisition of SpringWorks enhances its portfolio, potentially boosting revenue and market position in biotech, which could impact stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Nirogacestat may become the first approved therapy in the EU for desmoid tumors if it receives marketing authorization.
Why It Matters
Approval of nirogacestat would create a unique market position, potentially driving revenue growth for the company and attracting investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti, LLC is investigating Merck KGaA's proposed acquisition of SpringWorks Therapeutics for $47.00 per share to assess fairness for shareholders.
Why It Matters
The investigation into SpringWorks' sale to Merck highlights potential valuation concerns, impacting shareholder sentiment and stock price volatility before the deal's finalization.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About SWTX Stock
What is SpringWorks Therapeutics Inc.'s (SWTX) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, SpringWorks Therapeutics Inc. (SWTX) has a median price target of $47.00. The highest price target is $47.00 and the lowest is $47.00.
Is SWTX stock a good investment in 2026?
According to current analyst ratings, SWTX has 0 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $46.99. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SWTX stock?
Wall Street analysts predict SWTX stock could reach $47.00 in the next 12 months. This represents a 0.0% increase from the current price of $46.99. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is SpringWorks Therapeutics Inc.'s business model?
SpringWorks Therapeutics generates revenue by developing and commercializing therapies for rare diseases, focusing on unmet medical needs. The company leverages partnerships and collaborations to enhance its research capabilities and expand its therapeutic pipeline, aiming to bring effective treatments to market efficiently.
What is the highest forecasted price for SWTX SpringWorks Therapeutics Inc.?
The highest price target for SWTX is $47.00 from Michael Schmidt at Guggenheim, which represents a 0.0% increase from the current price of $46.99.
What is the lowest forecasted price for SWTX SpringWorks Therapeutics Inc.?
The lowest price target for SWTX is $47.00 from Michael Schmidt at Guggenheim, which represents a 0.0% increase from the current price of $46.99.
What is the overall SWTX consensus from analysts for SpringWorks Therapeutics Inc.?
The overall analyst consensus for SWTX is neutral. Out of 11 Wall Street analysts, 0 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $47.00.
How accurate are SWTX stock price projections?
Stock price projections, including those for SpringWorks Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 18, 2026 6:24 PM UTC